

\*\*\*\*Published March 2019\*\*\*\*

## MarketVIEW: Respiratory Syncytial Virus (RSV) vaccines (CAT: VAMV023)

<b>Product Name</b>	:	<b>MarketVIEW: Respiratory Syncytial Virus (RSV) vaccines</b>
<b>Description</b>	:	Global vaccine commercial opportunity assessment [52 countries]
<b>Contents</b>	:	Executive presentation (~220 slides.pdf) + 2 x MS-Excel forecast model(s) (.xls)
<b>Therapeutic Area</b>	:	<b>Novel respiratory vaccines: infant/maternal &amp; adult</b>
<b>Publication date</b>	:	March 2019
<b>Catalogue No</b>	:	VAMV023

### Background

Human **respiratory syncytial virus (RSV)** is one of the most common viruses to infect children worldwide and now increasingly is recognized as an important pathogen in adults, especially the elderly. Globally each year, there are over **33m** episodes of RSV-associated acute lower respiratory infection in children younger than 5 yrs of age resulting at least **3.2m** hospital admissions and **59,600** in hospital deaths (2015 estimation, Shi T *et al.*, 2017). In children below 5 yrs, the burden of RSV exceeds that of influenza and other respiratory viral pathogens. There is no specific treatment for RSV infection and for those children who require hospitalization (~1-2% of healthy), supportive therapy is still the mainstay of care. **Palivizumab** (anti-RSV monoclonal, **Synagis®**) has been FDA approved since 1998 for the prophylaxis of specific subsets of premature infants.

Despite serious setbacks in the late 1960s with a formalin-inactivated RSV vaccine, the RSV vaccine development field is now one of the most active in the industry. Major companies such as **Pfizer**, **GSK Biologicals**, **Janssen NV** and smaller biotech's e.g. **Novavax** have a range of vaccine approaches in active clinical development targeting all the recognized target populations. Newer long-acting monoclonal antibodies such as **MEDI8897** (MedImmune) are also being pursued.

This **MarketVIEW** product is a comprehensive Executive Presentation (~220 slides) and MS-Excel forecast model which investigate the scenario-based interplay and commercial potential of four RSV vaccine profiles in all relevant target groups (e.g. maternal, infant, adult "at risk" and elderly) to 2035. **52 countries**<sup>1</sup> and **sub-regions** are included in the model with expected public and private sector vaccination being indicated. A methodology has been created whereby country specific roll-out is forecasted according to specific local factors and RSV transmission patterns which may in turn influence RSV program adoption. The report contains a thorough review of current disease background/epidemiology and vaccinology with an emphasis on structural-based antigen engineering. An analysis of the R&D competitive environment is also provided. This product is ideally suited to organisations wishing to access an up-to-date advanced global quantification of the RSV vaccine opportunity.

<sup>1</sup> US, Canada, Australia, M5EU + Other EU1 and 2, Brazil, Argentina, Chile, Other PAHO, South Korea, Japan, Other International, India, China, Russia

## Methodology

**VacZine Analytics** has closely monitored all significant source material pertaining to RSV vaccines in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of respiratory based-pathogens, especially Pertussis (Tdap) and Influenza has also been utilised.

### PRODUCT CONTENTS:

Published March 2019 (CAT No: VAMV023)

\*\*\*\*This product is a [summary presentation \(.pdf\)](#), [a forecast model \(.xls\)](#)

### Contents – Summary presentation (.pdf)<sup>2</sup>

Contents

Author's notes

Executive summary

**[SECTION 1]** RSV vaccines: key commercial model outputs

**[SECTION 2]** RSV: introduction to the virus and disease background

**[SECTION 3]** RSV: disease epidemiology (infants & children)

**[SECTION 4]** RSV: disease epidemiology (adults and elderly)

**[SECTION 5]** RSV: vaccinology

**[SECTION 6]** RSV: vaccine research and development (R&D) pipeline

**[SECTION 7]** RSV: vaccines: modelling commercial potential

Bibliography

About **VacZine Analytics**

Disclaimer



**SNAPSHOT**

**PAGES: ~220 slides** fully referenced/sourced. Available in .pdf form

**Contents – Vaccine demand models x 2 (MS Excel-based)**

**Worksheets = >90 interconnected**

---

<sup>2</sup> Full contents i.e. title per slide is proprietary and only available upon valid request

**PRODUCT COST:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT (both deliverables) - USD **\$11,995.00**/ GBP **£9,225.00**# (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to the final invoice total

# - *indicative prevailing rate will be applied on date of transaction, third-party licenses may be restricted/vary*

**HOW TO ORDER:**

To order, please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com) This report can also be purchased online. Please review the **TERMS and CONDITIONS** of purchase.




**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and the “**spiral logo**” are UK Registered Trademarks, 2009

**BIBLIOGRAPHY**

~200 references – only available upon valid request



**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (a division of Assay Advantage Ltd).
2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.
3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.
4. If not purchased online invoices are payable within **thirty days** of the invoice date.
5. All proposals are quoted in **\$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.
6. The Company agrees not to disclose to any third-party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees, and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

**VacZine Analytics**

A division of Assay Advantage Ltd

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel: +44 (0) 1279 927049 / Fax: +44 (0) 1279 927049

E-mail: [info@vaczine-analytics.com](mailto:info@vaczine-analytics.com)

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics** © is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics** © and “the spiral logo” are UK Registered Trademarks, 2009

